Literature DB >> 28609357

The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.

James R Howe1, Kenneth Cardona, Douglas L Fraker, Electron Kebebew, Brian R Untch, Yi-Zarn Wang, Calvin H Law, Eric H Liu, Michelle K Kim, Yusuf Menda, Brian G Morse, Emily K Bergsland, Jonathan R Strosberg, Eric K Nakakura, Rodney F Pommier.   

Abstract

Small bowel neuroendocrine tumors (SBNETs) have been increasing in frequency over the past decades, and are now the most common type of small bowel tumor. Consequently, general surgeons and surgical oncologists are seeing more patients with SBNETs in their practices than ever before. The management of these patients is often complex, owing to their secretion of hormones, frequent presentation with advanced disease, and difficulties with making the diagnosis of SBNETs. Despite these issues, even patients with advanced disease can have long-term survival. There are a number of scenarios which commonly arise in SBNET patients where it is difficult to determine the optimal management from the published data. To address these challenges for clinicians, a consensus conference was held assembling experts in the field to review and discuss the available literature and patterns of practice pertaining to specific management issues. This paper summarizes the important elements from these studies and the recommendations of the group for these questions regarding the management of SBNET patients.

Entities:  

Mesh:

Year:  2017        PMID: 28609357      PMCID: PMC5502737          DOI: 10.1097/MPA.0000000000000846

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  130 in total

1.  ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

Authors:  Marianne Pavel; Eric Baudin; Anne Couvelard; Eric Krenning; Kjell Öberg; Thomas Steinmüller; Martin Anlauf; Bertram Wiedenmann; Ramon Salazar
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

2.  Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?

Authors:  Vincenzo Mazzaferro; Andrea Pulvirenti; Jorgelina Coppa
Journal:  J Hepatol       Date:  2007-07-26       Impact factor: 25.083

Review 3.  MR enterography in Crohn's disease: current consensus on optimal imaging technique and future advances from the SAR Crohn's disease-focused panel.

Authors:  David J Grand; Flavius F Guglielmo; Mahmoud M Al-Hawary
Journal:  Abdom Imaging       Date:  2015-06

4.  Survival and prognostic factors in patients with small bowel carcinoid tumour.

Authors:  K Landerholm; N Zar; R E Andersson; S E Falkmer; J Järhult
Journal:  Br J Surg       Date:  2011-08-19       Impact factor: 6.939

5.  Comparison of clinicopathologic factors in 122 patients with resected pancreatic and ileal neuroendocrine tumors from a single institution.

Authors:  Fadi S Dahdaleh; Daniel Calva-Cerqueira; Jennifer C Carr; Junlin Liao; James J Mezhir; Thomas M O'Dorisio; James R Howe
Journal:  Ann Surg Oncol       Date:  2011-08-16       Impact factor: 5.344

6.  Carcinoid tumors of the small-bowel: evaluation with 64-section CT-enteroclysis.

Authors:  Philippe Soyer; Anthony Dohan; Clarisse Eveno; Xavier Dray; Lounis Hamzi; Christine Hoeffel; Rachid Kaci; Mourad Boudiaf
Journal:  Eur J Radiol       Date:  2013-03-06       Impact factor: 3.528

Review 7.  Ileal carcinoid tumors and intestinal ischemia.

Authors:  L Strobbe; E D'Hondt; C Ramboer; H Ceuppens; P Hinnekens; M Verhamme
Journal:  Hepatogastroenterology       Date:  1994-10

Review 8.  Helical CT-enteroclysis in the detection of small-bowel tumours: a meta-analysis.

Authors:  Philippe Soyer; Mounir Aout; Christine Hoeffel; Eric Vicaut; Vinciane Placé; Mourad Boudiaf
Journal:  Eur Radiol       Date:  2012-08-04       Impact factor: 5.315

9.  Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease.

Authors:  A Frilling; J Li; E Malamutmann; K-W Schmid; A Bockisch; C E Broelsch
Journal:  Br J Surg       Date:  2009-02       Impact factor: 6.939

10.  18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors.

Authors:  Tina Binderup; Ulrich Knigge; Annika Loft; Birgitte Federspiel; Andreas Kjaer
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

View more
  78 in total

Review 1.  Carcinoid Tumors: Past, Present, and Future.

Authors:  James R Howe
Journal:  Indian J Surg Oncol       Date:  2020-05-09

2.  Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study.

Authors:  Nicole Brighi; Francesco Panzuto; Roberta Modica; Fabio Gelsomino; Manuela Albertelli; Sara Pusceddu; Sara Massironi; Giuseppe Lamberti; Maria Rinzivillo; Antongiulio Faggiano; Andrea Spallanzani; Diego Ferone; Natalie Prinzi; Roberta Elisa Rossi; Bruno Annibale; Anna Maria Colao; Davide Campana
Journal:  Oncologist       Date:  2019-11-06

3.  Resection of Primary Gastrointestinal Neuroendocrine Tumor Among Patients with Non-Resected Metastases Is Associated with Improved Survival: A SEER-Medicare Analysis.

Authors:  Diamantis I Tsilimigras; J Madison Hyer; Anghela Z Paredes; Aslam Ejaz; Jordan M Cloyd; Joal D Beane; Mary Dillhoff; Allan Tsung; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2021-01-05       Impact factor: 3.452

Review 4.  Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

Authors:  Andrew M Bellizzi
Journal:  Hum Pathol       Date:  2019-12-17       Impact factor: 3.466

Review 5.  The Landmark Series: Neuroendocrine Tumor Liver Metastases.

Authors:  Alexandra Gangi; James R Howe
Journal:  Ann Surg Oncol       Date:  2020-07-06       Impact factor: 5.344

6.  Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.

Authors:  Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Ioannis D Kostakis; Demetrios Moris; Dimitrios Schizas; Jordan M Cloyd; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2019-01-22       Impact factor: 3.452

7.  A novel preoperative risk score to predict lymph node positivity for rectal neuroendocrine tumors: An NCDB analysis to guide operative technique.

Authors:  Adriana C Gamboa; Yuan Liu; Rachel M Lee; Mohammad Y Zaidi; Charles A Staley; Maria C Russell; Kenneth Cardona; Patrick S Sullivan; Shishir K Maithel
Journal:  J Surg Oncol       Date:  2019-08-26       Impact factor: 3.454

8.  Contemporary indications for and outcomes of hepatic resection for neuroendocrine liver metastases.

Authors:  Steven D Scoville; Dimitrios Xourafas; Aslam M Ejaz; Allan Tsung; Timothy Pawlik; Jordan M Cloyd
Journal:  World J Gastrointest Surg       Date:  2020-04-27

9.  Small Bowel Neuroendocrine Tumors.

Authors:  Catherine G Tran; Scott K Sherman; James R Howe
Journal:  Curr Probl Surg       Date:  2020-05-15       Impact factor: 1.909

10.  Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2018-05-24       Impact factor: 3.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.